Investor Overview


About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Recent News

Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGS  -  4/7/2021
AUSTIN, Texas , April 7, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has implemented the first wave of Panorama AI innovations following the breakthrough results shared earlier from the SMART study. More »
Natera and Tesis Labs Announce Strategic Collaboration on Prenatal Genetic Testing  -  3/31/2021
AUSTIN, Texas , March 31, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, and Tesis Labs , a US multi-region lab services provider with labs in Colorado, Texas and Arizona , announced a strategic partnership in More »
FDA Grants Two New Breakthrough Device Designations for Natera's Signatera™ MRD Test  -  3/24/2021
Designations help accelerate the regulatory review and approval of Signatera across a variety of solid tumor indications AUSTIN, Texas , March 24, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the US Food and Drug More »
Natera and Genentech Initiate Phase III Trial Using Signatera™ as a Companion Diagnostic for Atezolizumab in Early-Stage Muscle-Invasive Bladder Cancer  -  3/10/2021
Signatera used to identify muscle-invasive urothelial carcinoma patients who are MRD-positive after surgery, for enrollment in IMvigor011 study evaluating adjuvant immunotherapy with atezolizumab AUSTIN, Texas , March 10, 2021 /PRNewswire/ --  Natera, Inc. More »
Natera Reports Fourth Quarter and Year 2020 Financial Results  -  2/25/2021
SAN CARLOS, Calif., Feb. 25, 2021 /PRNewswire/ — Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided an update on recent business progress. More »

Upcoming Events

More events are coming soon.

Past events

Tuesday, 03/02/21 at 11:10 AM PST

Footer disclaimer

Footer disclaimer

© Natera 2021. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.